1. Home
  2. ONC vs KEYS Comparison

ONC vs KEYS Comparison

Compare ONC & KEYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ONC
  • KEYS
  • Stock Information
  • Founded
  • ONC 2010
  • KEYS 1939
  • Country
  • ONC Switzerland
  • KEYS United States
  • Employees
  • ONC N/A
  • KEYS N/A
  • Industry
  • ONC Biotechnology: Pharmaceutical Preparations
  • KEYS Industrial Machinery/Components
  • Sector
  • ONC Health Care
  • KEYS Industrials
  • Exchange
  • ONC Nasdaq
  • KEYS Nasdaq
  • Market Cap
  • ONC 34.8B
  • KEYS 29.8B
  • IPO Year
  • ONC N/A
  • KEYS N/A
  • Fundamental
  • Price
  • ONC $368.19
  • KEYS $179.19
  • Analyst Decision
  • ONC Strong Buy
  • KEYS Buy
  • Analyst Count
  • ONC 12
  • KEYS 11
  • Target Price
  • ONC $361.00
  • KEYS $192.18
  • AVG Volume (30 Days)
  • ONC 252.8K
  • KEYS 1.3M
  • Earning Date
  • ONC 11-06-2025
  • KEYS 11-24-2025
  • Dividend Yield
  • ONC N/A
  • KEYS N/A
  • EPS Growth
  • ONC N/A
  • KEYS N/A
  • EPS
  • ONC 0.29
  • KEYS 3.14
  • Revenue
  • ONC $4,998,489,124.00
  • KEYS $5,243,000,000.00
  • Revenue This Year
  • ONC $887.89
  • KEYS $9.38
  • Revenue Next Year
  • ONC $22.45
  • KEYS $6.33
  • P/E Ratio
  • ONC $1,226.72
  • KEYS $57.09
  • Revenue Growth
  • ONC 49.15
  • KEYS 4.80
  • 52 Week Low
  • ONC $170.99
  • KEYS $121.43
  • 52 Week High
  • ONC $381.50
  • KEYS $187.67
  • Technical
  • Relative Strength Index (RSI)
  • ONC 66.75
  • KEYS 53.71
  • Support Level
  • ONC $306.60
  • KEYS $181.36
  • Resistance Level
  • ONC $381.50
  • KEYS $185.90
  • Average True Range (ATR)
  • ONC 12.71
  • KEYS 5.44
  • MACD
  • ONC 6.69
  • KEYS 0.08
  • Stochastic Oscillator
  • ONC 80.96
  • KEYS 63.07

About ONC BeiGene Ltd. American Depositary Shares

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.

About KEYS Keysight Technologies Inc.

Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.

Share on Social Networks: